Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sage Therapeutics

7.37
-0.1700-2.25%
Post-market: 7.500.1300+1.76%16:34 EDT
Volume:608.40K
Turnover:4.49M
Market Cap:453.11M
PE:-1.12
High:7.47
Open:7.45
Low:7.28
Close:7.54
Loading ...

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

Business Wire
·
15 Apr

US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert

Benzinga
·
27 Mar

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?

Zacks
·
13 Mar

Sage Therapeutics resumed with an Underperform at BofA

TIPRANKS
·
11 Mar

SAGE Therapeutics Announces CMO Resignation and Interim Appointment

TIPRANKS
·
05 Mar

BRIEF-SAGE Therapeutics Announces Research And Development Leadership Transition

Reuters
·
05 Mar

Sage Therapeutics Announces R&D Leadership Transition

THOMSON REUTERS
·
05 Mar

Sage Therapeutics Announces R&D Leadership Transition

Business Wire
·
05 Mar

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

Insider Monkey
·
02 Mar

SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial

TIPRANKS
·
13 Feb

SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth

TIPRANKS
·
13 Feb

Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects

TIPRANKS
·
13 Feb

SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges

TIPRANKS
·
13 Feb

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

Zacks
·
13 Feb

Sage Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
13 Feb

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

TIPRANKS
·
12 Feb

Sage Therapeutics Price Target Cut to $12.00/Share From $14.00 by HC Wainwright & Co.

Dow Jones
·
12 Feb

SAGE Therapeutics (SAGE) Gets a Buy from Scotiabank

TIPRANKS
·
12 Feb

SAGE Therapeutics (SAGE) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
12 Feb